200 related articles for article (PubMed ID: 8239608)
1. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.
McGrath BJ; Lamp KC; Rybak MJ
Antimicrob Agents Chemother; 1993 Sep; 37(9):1931-7. PubMed ID: 8239608
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
3. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
[TBL] [Abstract][Full Text] [Related]
5. Single daily dosing of amikacin in an in-vitro model.
Dudley MN; Zinner SH
J Antimicrob Chemother; 1991 May; 27 Suppl C():15-9. PubMed ID: 1906862
[TBL] [Abstract][Full Text] [Related]
6. Imipenem/Cilastatin/Relebactam Alone and in Combination against
Chen IH; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33139283
[TBL] [Abstract][Full Text] [Related]
7. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
[TBL] [Abstract][Full Text] [Related]
8. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
McGrath BJ; Bailey EM; Lamp KC; Rybak MJ
Antimicrob Agents Chemother; 1992 Dec; 36(12):2741-6. PubMed ID: 1482142
[TBL] [Abstract][Full Text] [Related]
10.
Asempa TE; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262769
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
[TBL] [Abstract][Full Text] [Related]
12. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Chan E; Zhou S; Srikumar S; Duan W
Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.
Avent ML; McCarthy KL; Sime FB; Naicker S; Heffernan AJ; Wallis SC; Paterson DL; Roberts JA
Microbiol Spectr; 2022 Jun; 10(3):e0052522. PubMed ID: 35442072
[TBL] [Abstract][Full Text] [Related]
14. [Effect of superinhibitory levels of imipenem and amikacin singly or in combination on Pseudomonas aeruginosa].
Hostacká A
Epidemiol Mikrobiol Imunol; 1997 Dec; 46(4):155-7. PubMed ID: 9471306
[TBL] [Abstract][Full Text] [Related]
15. Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa.
Gerçeker AA; Otük G
Chemotherapy; 1995; 41(6):433-6. PubMed ID: 8529433
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of imipenem and amikacin combinations against resistant Pseudomonas aeruginosa.
Fujita J; Negayama K; Takigawa K; Yamagishi Y; Yamaji Y; Kawanishi K; Takahara J
J Antimicrob Chemother; 1993 Jun; 31(6):1007-9. PubMed ID: 8360119
[No Abstract] [Full Text] [Related]
17. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
Yadav R; Bulitta JB; Schneider EK; Shin BS; Velkov T; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.
Cappelletty DM
Antimicrob Agents Chemother; 1999 Jan; 43(1):129-33. PubMed ID: 9869577
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa.
Heffernan AJ; Sime FB; Naicker S; Andrews K; Ellwood D; Guerra-Valero Y; Wallis S; Lipman J; Grimwood K; Roberts JA
Diagn Microbiol Infect Dis; 2021 Jun; 100(2):115329. PubMed ID: 33714790
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
